Starfleet Innotech Signs Binding Agreement with European Wellness to Pioneer New Medical Tourism Ventures in the Asia-Pacific
New York, New York–(Newsfile Corp. – March 31, 2023) – Starfleet Innotech, Inc. (OTC Pink:…
New York, New York–(Newsfile Corp. – March 31, 2023) – Starfleet Innotech, Inc. (OTC Pink:…
New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact…
New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact…
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 Signed…
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 Signed…
YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop…
SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop…
MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of…
~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of…
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
$17.5 Million in Cash and Marketable Securities as of December 31, 2022; Expected to Support…
$17.5 Million in Cash and Marketable Securities as of December 31, 2022; Expected to Support…
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma,…